Intercept Drug’s Market Standing In PBC Undermined By Safety Woes
Ocaliva Now Contraindicated In Advanced Cirrhosis
A second FDA safety labeling update for Intercept’s Ocaliva might open a market opportunity in second-line PBC for Phase III candidates at CymaBay and Genfit.
You may also be interested in...
Genfit Pivots To Opposite End Of The Liver Disease Spectrum
Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.
Ipsen Gives Genfit Liver Drug New Lease Of Life
The French biotech was firmly on the ropes last year after elafibranor joined the long list of failures for NASH but the promise it has shown in primary biliary cholangitis has persuaded Ipsen to part with a hefty upfront fee.
CymaBay Builds Seladelpar Case In PBC, But Door Not Closed On NASH
The company pointed to cirrhosis benefit and less pruritis in a pooled analysis presented at EASL, which will help it will take on Intercept in primary biliary cholangitis on tolerability, cirrhosis benefit.